Business
GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunothera...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ","length":79,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious diseases and cancer, today reinforced the strategic and commercial significance of the recent positive Scientific Advice (SA) received from the European Medicines Agency (EMA) for its GEO-MVA vaccine targeting Mpox and smallpox.","length":421,"tagName":"p"},{"type":"text","content":"The EMA's feedback indicated that a single Phase 3 immuno-bridging trial, bypassing the need for Phase 1 and 2 studies, may be sufficient to support a Marketing Authorization Application (MAA) under the EU's centralized procedure. The ability to proceed without Phase 1 and 2 clinical trials substantially reduces development risk and timelines, positioning GeoVax to achieve product commercialization and revenue generation significantly earlier than previously anticipated.","length":483,"tagName":"p"},{"type":"text","content":"Immuno-bridging studies allow for vaccine approval by the immune response elicited by a candidate vaccine comparable to that of an already approved vaccine. This approach, when accepted by regulatory authorities, can reduce the need for large-scale efficacy trials, thereby reducing development time while maintaining regulatory standards for safety and immunogenicity.","length":369,"tagName":"p"},{"type":"text","content":""This EMA guidance is more than a regulatory milestone; it represents a potential commercial inflection point," said David Dodd, Chairman and CEO of GeoVax. "We now have a clear, expedited path to commercialization in one of the world's largest vaccine markets. With t...